RxDoctor Payments Data

Roshin Mathew, MD

Cardiovascular Disease · Atlanta, GANPI 1881983963

Payments from drug & device makers

$3,013in general payments, 2019–2025

Across 125 payments — averaging $24.11 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novartis$620
  • Siemens Medical Solutions USA, Inc.$482
  • Johnson & Johnson$435
  • ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)$193
  • Amgen$160
  • AstraZeneca$157
  • plus $965 from 16 others

What the payments were for

  • Food & beverage$3,013100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$3,013 in reported general payments places this provider in the 50th percentile of 640 cardiovascular disease providers in Georgia.

See all cardiovascular disease providers in Georgia

Medicare billing

Part B allowed, 2024
$94,972
Medicare patients
712
Services billed
1,303

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban41$60,784
EntrestoSacubitril/Valsartan12$11,520
Metoprolol Succinate100$1,257
Rosuvastatin Calcium60$949
Ezetimibe13$580
Atorvastatin Calcium43$449
Losartan Potassium50$356
Isosorbide Mononitrate ErIsosorbide Mononitrate17$295
Amlodipine Besylate46$251
Carvedilol34$232
ClopidogrelClopidogrel Bisulfate41$218
Furosemide49$181
Spironolactone21$164
Metoprolol Tartrate39$90
Pantoprazole Sodium12$88

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$116$60,78441 claims
NovartisEntresto$620$11,52012 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 50th percentile of 640 cardiovascular disease providers in Georgia.

Other cardiovascular disease in Atlanta

See the full list for Georgia

Where these figures come from

Is this you, or does something look wrong? →